Goodwill and Intangible Assets

6 Months Ended

Mar. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

(14) Goodwill and Intangible Assets

Goodwill

A rollforward of goodwill activity by reportable segment from September 29, 2012 to March 30, 2013 was as follows:


	Breast Health			Diagnostics			GYN Surgical		Skeletal Health			Total
Balance at September 29, 2012	$	635,741		$	2,283,447		$	1,015,466	$	8,125		$	3,942,779
Gen-Probe acquisition adjustments		—			(2,146	)		—		—			(2,146	)
Chindex acquisition		1,903			—			—		—			1,903
Tax adjustments		—			(545	)		12		—			(533	)
Foreign currency		(1,614	)		255			666		(1	)		(694	)

Balance at March 30, 2013	$	636,030		$	2,281,011		$	1,016,144	$	8,124		$	3,941,309

Intangible Assets

Intangible assets consisted of the following:


Description	As of March 30, 2013				As of September 29, 2012
Description	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Developed technology	$	3,816,465	$	938,655	$	3,784,689	$	788,274
In-process research and development		193,000		—		227,000		—
Customer relationships and contracts		1,101,232		250,972		1,097,842		205,612
Trade names		238,077		72,027		240,092		60,318
Patents		11,940		8,109		11,417		7,906
Business licenses		2,607		478		2,577		344
Non-competition agreements		306		270		310		223

Totals	$	5,363,627	$	1,270,511	$	5,363,927	$	1,062,677

The estimated remaining amortization expense as of March 30, 2013 for each of the five succeeding fiscal years was as follows:


Remainder of Fiscal 2013	$	205,733
Fiscal 2014		398,978
Fiscal 2015		384,088
Fiscal 2016		370,306
Fiscal 2017		361,254

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details